PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)
Nov 1, 2006, 00:00
10.1016/S1098-3015(10)63453-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)63453-5/fulltext
Title :
PCN23 ADDING RITUXIMAB TO STANDARD CHEMOTHERAPY IS COST NEUTRAL AND CLINICALLY SUPERIOR IN ADVANCED STAGE NON-HODGKIN'S LYMPHOMA (NHL)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63453-5&doi=10.1016/S1098-3015(10)63453-5
First page :
Section Title :
Open access? :
No
Section Order :
303